Trial Profile
Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 07 Mar 2021 Status changed from recruiting to completed.
- 15 May 2020 Planned End Date changed from 1 Jul 2022 to 1 Sep 2021.
- 15 May 2020 Planned primary completion date changed from 1 Jul 2021 to 1 May 2020.